{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:10:22Z","timestamp":1770837022722,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04441-2","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T17:03:43Z","timestamp":1768669423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bipolar androgen therapy as platform for personalized medicine in castration-resistant prostate cancer"],"prefix":"10.1007","volume":"17","author":[{"given":"Wolfgang","family":"Lilleby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Geinitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Denmeade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"issue":"2","key":"4441_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard First-Line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121\u201331.","journal-title":"N Engl J Med"},{"issue":"6","key":"4441_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/oncolo\/oyad055","volume":"28","author":"SR Denmeade","year":"2023","unstructured":"Denmeade SR, Sena LA, Wang H, Antonarakis ES, Markowski MC. Bipolar androgen therapy followed by androgen receptor Inhibition as sequential therapy for prostate cancer. Oncologist. 2023;28(6):465\u201373.","journal-title":"Oncologist"},{"issue":"14","key":"4441_CR3","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/pros.21196","volume":"70","author":"SR Denmeade","year":"2010","unstructured":"Denmeade SR, Isaacs JT. Bipolar androgen therapy: the rationale for rapid cycling of Supraphysiologic androgen\/ablation in men with castration resistant prostate cancer. Prostate. 2010;70(14):1600\u20137.","journal-title":"Prostate"},{"issue":"5","key":"4441_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41585-022-00686-y","volume":"20","author":"R Kumar","year":"2023","unstructured":"Kumar R, Sena LA, Denmeade SR, Kachhap S. The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications. Nat Rev Urol. 2023;20(5):265\u201378.","journal-title":"Nat Rev Urol"},{"issue":"6","key":"4441_CR5","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1158\/0008-5472.CAN-04-3992","volume":"65","author":"CP Chuu","year":"2005","unstructured":"Chuu CP, Hiipakka RA, Fukuchi J, Kokontis JM, Liao S. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res. 2005;65(6):2082\u20134.","journal-title":"Cancer Res"},{"issue":"4","key":"4441_CR6","first-page":"232","volume":"22","author":"C Huggins","year":"1972","unstructured":"Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of Estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22(4):232\u201340.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"4441_CR7","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1158\/1078-0432.CCR-08-2036","volume":"15","author":"MA Leversha","year":"2009","unstructured":"Leversha MA, Han J, Asgari Z, Danila DC, Lin O, Gonzalez-Espinoza R, et al. Fluorescence in situ hybridization analysis of Circulating tumor cells in metastatic prostate cancer. Clin Cancer Res. 2009;15(6):2091\u20137.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4441_CR8","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1158\/0008-5472.CAN-08-3667","volume":"69","author":"G Attard","year":"2009","unstructured":"Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A\u2019Hern R, et al. Characterization of ERG, AR and PTEN gene status in Circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 2009;69(7):2912\u20138.","journal-title":"Cancer Res"},{"key":"4441_CR9","doi-asserted-by":"crossref","unstructured":"Sena LA, Kumar R, Sanin DE, Thompson EA, Rosen DM, Dalrymple SL et al. Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC. J Clin Invest. 2022;132(23) 1-13.","DOI":"10.1172\/JCI162396"},{"key":"4441_CR10","doi-asserted-by":"crossref","unstructured":"Torabinejad S, Miro C, Barone B, Imbimbo C, Crocetto F, Dentice M. The androgen-thyroid hormone crosstalk in prostate cancer and the clinical implications. Eur Thyroid J. 2023;12(3)e220228 .","DOI":"10.1530\/ETJ-22-0228"},{"issue":"6","key":"4441_CR11","doi-asserted-by":"publisher","first-page":"647","DOI":"10.4161\/cc.6.6.4028","volume":"6","author":"DJ Vander Griend","year":"2007","unstructured":"Vander Griend DJ, Litvinov IV, Isaacs JT. Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation. Cell Cycle. 2007;6(6):647\u201351.","journal-title":"Cell Cycle"},{"issue":"1","key":"4441_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/pros.24798","volume":"85","author":"EU Tran","year":"2025","unstructured":"Tran EU, Royz E, Yamamoto K, Marley S, Song A, Pan E, et al. Bipolar androgen therapy for treatment of metastatic castration-resistant prostate cancer: A case series. Prostate. 2025;85(1):40\u20137.","journal-title":"Prostate"},{"issue":"12","key":"4441_CR13","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1200\/JCO.20.02759","volume":"39","author":"SR Denmeade","year":"2021","unstructured":"Denmeade SR, Wang H, Agarwal N, Smith DC, Schweizer MT, Stein MN, et al. TRANSFORMER: A randomized phase II study comparing bipolar androgen therapy versus enzalutamide in asymptomatic men with Castration-Resistant metastatic prostate cancer. J Clin Oncol. 2021;39(12):1371\u201382.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4441_CR14","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.eururo.2020.06.042","volume":"79","author":"MC Markowski","year":"2021","unstructured":"Markowski MC, Wang H, Sullivan R, Rifkind I, Sinibaldi V, Schweizer MT, et al. A multicohort Open-label phase II trial of bipolar androgen therapy in men with metastatic Castration-resistant prostate cancer (RESTORE): A comparison of Post-abiraterone versus Post-enzalutamide cohorts. Eur Urol. 2021;79(5):692\u20139.","journal-title":"Eur Urol"},{"issue":"14","key":"4441_CR15","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754\u201360.","journal-title":"Bioinformatics"},{"issue":"24","key":"4441_CR16","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","volume":"383","author":"M Hussain","year":"2020","unstructured":"Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Survival with Olaparib in metastatic Castration-Resistant prostate cancer. N Engl J Med. 2020;383(24):2345\u201357.","journal-title":"N Engl J Med"},{"issue":"312","key":"4441_CR17","doi-asserted-by":"publisher","first-page":"312fs45","DOI":"10.1126\/scitranslmed.aad4008","volume":"7","author":"MT Schweizer","year":"2015","unstructured":"Schweizer MT, Antonarakis ES. Liquid biopsy: clues on prostate cancer drug resistance. Sci Transl Med. 2015;7(312):312fs45.","journal-title":"Sci Transl Med"},{"issue":"2","key":"4441_CR18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","volume":"9","author":"KK Lin","year":"2019","unstructured":"Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, et al. BRCA reversion mutations in Circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor Rucaparib in High-Grade ovarian carcinoma. Cancer Discov. 2019;9(2):210\u20139.","journal-title":"Cancer Discov"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04441-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04441-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04441-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:18:02Z","timestamp":1770833882000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04441-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4441"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04441-2","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work contains genomic findings approved by the institutional tumour board (em professor Eivind Hovig, dr. Kjetil Berner).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The listed authors, Wolfgang Lilleby, Hans Geinitz and Samuel Denmeade have substantially contributed to the article and accepted the final version.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki (in its most recently amended version). All procedures followed were in accordance with the ethical standards as required by national law. The patient gave his written consent to publish his case.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"293"}}